{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:11:40Z","timestamp":1761487900402},"reference-count":37,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"vor","delay-in-days":4513,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1093\/annonc\/mdm180","type":"journal-article","created":{"date-parts":[[2007,8,11]],"date-time":"2007-08-11T11:12:39Z","timestamp":1186830759000},"page":"1388-1394","source":"Crossref","is-referenced-by-count":18,"title":["An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon-\u03b12b in patients with multiple myeloma maintained on a steady dose of interferon-\u03b12b"],"prefix":"10.1016","volume":"18","author":[{"given":"B","family":"Sirohi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Powles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Treleaven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Leary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Rudin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Horton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdm180_bb0010","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdm180_bb0015","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2002.02.116","article-title":"Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma","volume":"21","author":"Rajkumar","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm180_bb0020","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","article-title":"Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdm180_bb0025","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","article-title":"Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdm180_bb0030","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdm180_bb0035","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1365-2141.2005.05519.x","article-title":"PAD combination therapy (PS-341\/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma","volume":"129","author":"Oakervee","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdm180_bb0040","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3816\/CLM.2003.n.022","article-title":"A prospective, open-label safety and efficacy study of combination treatment with bortezomib (PS-341, velcade and melphalan in patients with relapsed or refractory multiple myeloma","volume":"4","author":"Yang","year":"2003","journal-title":"Clin Lymphoma"},{"key":"10.1093\/annonc\/mdm180_bb0045","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1182\/blood.V97.9.2574","article-title":"High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions","volume":"97","author":"Badros","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdm180_bb0050","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/sj.bmt.1705000","article-title":"An elective single autograft with high-dose melphalan: single-center study of 451 patients","volume":"36","author":"Sirohi","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mdm180_bb0055","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdm180_bb0060","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1023\/A:1015096313594","article-title":"Evaluating high dose therapy in multiple myeloma: use of quality-adjusted survival analysis","volume":"11","author":"Porcher","year":"2002","journal-title":"Qual Life Res"},{"key":"10.1093\/annonc\/mdm180_bb0065","doi-asserted-by":"crossref","first-page":"231a","DOI":"10.1182\/blood.V106.11.782.782","article-title":"Thalidomide-dexamethasone versus melphalan-prednisolone as first line treatment in elderly patients with multiple myeloma: an interim analysis","volume":"106","author":"Ludwig","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdm180_bb0070","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdm180_bb0075","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1086\/429498","article-title":"Clinical trials of treatment for hepatitis C virus infection in HIV-infected patients: past, present, and future","volume":"41","author":"Shire","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1093\/annonc\/mdm180_bb0080","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdm180_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta8390","article-title":"Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation","volume":"8","author":"Shepherd","year":"2004","journal-title":"Health Technol Assess"},{"key":"10.1093\/annonc\/mdm180_bb0090","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1023\/A:1026548226770","article-title":"Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients","volume":"11","author":"Ludwig","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdm180_bb0095","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1365-2141.2001.02857.x","article-title":"Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients","volume":"113","author":"The Myeloma Trialists' Collaborative Group","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdm180_bb0100","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/cncr.10663","article-title":"Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation","volume":"95","author":"Bukowski","year":"2002","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdm180_bb0105","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdm180_bb0110","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1046\/j.1365-2141.1999.01206.x","article-title":"Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma","volume":"104","author":"Stead","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdm180_bb0115","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1200\/JCO.1995.13.5.1249","article-title":"Test\/retest study of the European Organisation for Research and Treatment of Cancer core quality-of-life questionnaire","volume":"13","author":"Hjermstad","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm180_bb0120","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0360-3016(99)00559-3","article-title":"Common toxicity criteria: version 2.0: an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy","volume":"47","author":"Trotti","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdm180_bb0125","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdm180_bb0130","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant","volume":"102","author":"Blad\u00e9","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdm180_bb0135","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(79)90770-0","article-title":"Interferon therapy in myelomatosis","volume":"i","author":"Mellstedt","year":"1979","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdm180_bb0140","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJM199005173222005","article-title":"Maintenance treatment with recombinant interferon alpha 2b in patients with multiple myeloma responding to conventional induction chemotherapy","volume":"322","author":"Mandelli","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdm180_bb0145","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1046\/j.1365-2141.1998.00795.x","article-title":"A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results","volume":"102","author":"Cunningham","year":"1998","journal-title":"Br J Hematol"},{"key":"10.1093\/annonc\/mdm180_bb0150","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1182\/blood.V92.6.2184","article-title":"The Italian experience on interferon as maintenance treatment in multiple myeloma: ten years after","volume":"92","author":"Pulsoni","year":"1998","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdm180_bb0155","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1365-2141.1998.00648.x","article-title":"MRC trial of a2b-interferon maintenance therapy in first plateau phase of multiple myeloma","volume":"101","author":"Drayson","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdm180_bb0160","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1200\/JCO.1995.13.9.2354","article-title":"Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group","volume":"13","author":"Browman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm180_bb0165","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/sj.leu.2401039","article-title":"Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology)","volume":"12","author":"Blade","year":"1998","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdm180_bb0170","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.1994.12.11.2405","article-title":"Combination chemotherapy, glucocorticoids and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group Study","volume":"12","author":"Salmon","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm180_bb0175","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/annonc\/mdi125","article-title":"Interferon-\u03b1 as maintenance therapy in patients with multiple myeloma","volume":"16","author":"Schaar","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdm180_bb0180","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1200\/JCO.1997.15.4.1672","article-title":"Patient preferences for interferon alfa in multiple myeloma","volume":"15","author":"Ludwig","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm180_bb0185","first-page":"179","article-title":"Comparison of interferon tolerance after autologous bone marrow or peripheral blood stem cell transplants for myeloma patients who have responded to induction therapy","volume":"18","author":"Powles","year":"1995","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdm180_bb0190","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1191\/0962280204sm357ra","article-title":"Patient reported outcomes as endpoints in medical research","volume":"13","author":"Fairclough","year":"2004","journal-title":"Stat Methods Med Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419429074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419429074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/18\/8\/1388\/19446716\/mdm180.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T20:02:50Z","timestamp":1587844970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419429074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["S0923753419429074"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdm180","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}